Exploring the role of ubiquitin regulatory X domain family proteins in cancers: bioinformatics insights, mechanisms, and implications for therapy
Abstract UBXD family (UBXDF), a group of proteins containing ubiquitin regulatory X (UBX) domains, play a crucial role in the imbalance of proliferation and apoptotic in cancer. In this study, we summarised bioinformatics proof on multi-omics databases and literature on UBXDF’s effects on cancer. Bioinformatics analysis revealed that Fas-associated factor 1 (FAF1) has the largest number of gene alterations in the UBXD family and has been linked to survival and cancer progression in many cancers. UBXDF may affect tumour microenvironment (TME) and drugtherapy and should be investigated in the future. We also summarised the experimental evidence of the mechanism of UBXDF in cancer, both in vitro and in vivo, as well as its application in clinical and targeted drugs. We compared bioinformatics and literature to provide a multi-omics insight into UBXDF in cancers, review proof and mechanism of UBXDF effects on cancers, and prospect future research directions in-depth. We hope that this paper will be helpful for direct cancer-related UBXDF studies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Journal of translational medicine - 22(2024), 1 vom: 15. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Enyu [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12967-024-04890-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR05480275X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05480275X | ||
| 003 | DE-627 | ||
| 005 | 20240217064644.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240217s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12967-024-04890-9 |2 doi | |
| 035 | |a (DE-627)SPR05480275X | ||
| 035 | |a (SPR)s12967-024-04890-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Enyu |e verfasserin |0 (orcid)0000-0003-1441-1276 |4 aut | |
| 245 | 1 | 0 | |a Exploring the role of ubiquitin regulatory X domain family proteins in cancers: bioinformatics insights, mechanisms, and implications for therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Abstract UBXD family (UBXDF), a group of proteins containing ubiquitin regulatory X (UBX) domains, play a crucial role in the imbalance of proliferation and apoptotic in cancer. In this study, we summarised bioinformatics proof on multi-omics databases and literature on UBXDF’s effects on cancer. Bioinformatics analysis revealed that Fas-associated factor 1 (FAF1) has the largest number of gene alterations in the UBXD family and has been linked to survival and cancer progression in many cancers. UBXDF may affect tumour microenvironment (TME) and drugtherapy and should be investigated in the future. We also summarised the experimental evidence of the mechanism of UBXDF in cancer, both in vitro and in vivo, as well as its application in clinical and targeted drugs. We compared bioinformatics and literature to provide a multi-omics insight into UBXDF in cancers, review proof and mechanism of UBXDF effects on cancers, and prospect future research directions in-depth. We hope that this paper will be helpful for direct cancer-related UBXDF studies. | ||
| 650 | 4 | |a UBXD |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Bioinformatic |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cancers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mechanism |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drugtherapy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Fan, Xiaowei |4 aut | |
| 700 | 1 | |a Ye, Haihan |4 aut | |
| 700 | 1 | |a Sun, Xiaoyang |4 aut | |
| 700 | 1 | |a Ji, Qing |4 aut | |
| 700 | 1 | |a Ding, Qianyun |4 aut | |
| 700 | 1 | |a Zhong, Shulian |4 aut | |
| 700 | 1 | |a Zhao, Shuo |4 aut | |
| 700 | 1 | |a Xuan, Cheng |4 aut | |
| 700 | 1 | |a Fang, Meiyu |0 (orcid)0000-0001-9369-3640 |4 aut | |
| 700 | 1 | |a Ding, Xianfeng |0 (orcid)0000-0003-1119-3816 |4 aut | |
| 700 | 1 | |a Cao, Jun |0 (orcid)0000-0001-6920-1669 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of translational medicine |d London : BioMed Central, 2003 |g 22(2024), 1 vom: 15. Feb. |w (DE-627)SPR028930886 |w (DE-600)2118570-0 |x 1479-5876 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:1 |g day:15 |g month:02 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12967-024-04890-9 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 1 |b 15 |c 02 | ||